- Home
- IDR vs TOI Comparison
IDR vs TOI Comparison
Compare IDR & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- TOI
- Stock Information
- Founded
- IDR 1996
- TOI 2007
- Country
- IDR United States
- TOI United States
- Employees
- IDR N/A
- TOI N/A
- Industry
- IDR Precious Metals
- TOI Medical/Nursing Services
- Sector
- IDR Basic Materials
- TOI Health Care
- Exchange
- IDR Nasdaq
- TOI Nasdaq
- Market Cap
- IDR 378.0M
- TOI 444.1M
- IPO Year
- IDR N/A
- TOI N/A
- Fundamental
- Price
- IDR $34.85
- TOI $3.89
- Analyst Decision
- IDR Strong Buy
- TOI Strong Buy
- Analyst Count
- IDR 1
- TOI 2
- Target Price
- IDR $17.50
- TOI $6.50
- AVG Volume (30 Days)
- IDR 589.8K
- TOI 2.7M
- Earning Date
- IDR 11-12-2025
- TOI 11-13-2025
- Dividend Yield
- IDR N/A
- TOI N/A
- EPS Growth
- IDR 52.70
- TOI N/A
- EPS
- IDR 0.73
- TOI N/A
- Revenue
- IDR $35,424,313.00
- TOI $461,039,000.00
- Revenue This Year
- IDR $21.91
- TOI $21.71
- Revenue Next Year
- IDR $5.47
- TOI $20.58
- P/E Ratio
- IDR $48.40
- TOI N/A
- Revenue Growth
- IDR 61.35
- TOI 21.67
- 52 Week Low
- IDR $9.67
- TOI $0.13
- 52 Week High
- IDR $54.70
- TOI $4.88
- Technical
- Relative Strength Index (RSI)
- IDR 52.29
- TOI 51.59
- Support Level
- IDR $31.06
- TOI $3.07
- Resistance Level
- IDR $33.88
- TOI $3.47
- Average True Range (ATR)
- IDR 3.25
- TOI 0.34
- MACD
- IDR 0.12
- TOI -0.11
- Stochastic Oscillator
- IDR 94.32
- TOI 52.74
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.